Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of RQ3013 as a heterologous booster after 3 doses of inactivated COVID-19 vaccine
ChiCTR2200067184Phase 3Not yet recruiting
- Sponsor
- Anning City First People's Hospital
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RQ3013 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Anning City First People's Hospital. Primary endpoints: Person-year incidence rate of symptomatic COVID-19 and Safety after one booster dose. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
RQ3013
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200067184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067184.